NET-4 Inhibitors
NET-4 inhibitors constitute a distinctive chemical class that revolves around their ability to modulate the enzymatic activity of NET-4, an enzyme with intricate implications in various biochemical cascades. The chemical structure and design of these inhibitors are tailored to interact with the active site of the NET-4 enzyme, which is meticulously studied to comprehend its structural and functional characteristics. This tailored interaction often involves the exploitation of intermolecular forces such as hydrogen bonding, electrostatic interactions, and hydrophobic contacts, allowing the inhibitor to bind to the enzyme with remarkable specificity. NET-4, as the target of these inhibitors, is strategically chosen due to its participation in crucial cellular signaling pathways.
By specifically inhibiting NET-4, researchers can gain valuable insights into the downstream effects of modulating this enzyme's activity. The selectivity of NET-4 inhibitors is a hallmark of their design, ensuring that they predominantly affect the NET-4 enzyme without inadvertently influencing closely related enzymes or cellular processes. In essence, NET-4 inhibitors represent a remarkable achievement in the realm of chemical biology, serving as indispensable tools for studying the complexities of cellular signaling pathways where NET-4 operates. Through their precise and tailored interactions with the enzyme, these inhibitors facilitate the dissection of intricate biochemical processes, contributing to the advancement of knowledge in molecular biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
Imatinib inhibits the activity of the Bcr-Abl kinase, which is constitutively active in chronic myeloid leukemia (CML). It competitively binds to the ATP-binding site of Bcr-Abl, blocking downstream signaling pathways that promote cell proliferation and survival. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib targets multiple tyrosine kinases, including Bcr-Abl and Src family kinases. It binds to the ATP-binding sites of these kinases, inhibiting their activity and interfering with signaling pathways that contribute to cancer cell growth and survival. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is another Bcr-Abl kinase inhibitor. It competes with ATP for binding to the kinase domain of Bcr-Abl, disrupting downstream signaling cascades essential for leukemic cell proliferation. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
AP 24534 (Ponatinib) is a potent Bcr-Abl inhibitor used for resistant CML cases. It targets native and mutant forms of Bcr-Abl by irreversibly binding to the ATP-binding site, inhibiting the kinase and interfering with downstream oncogenic pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits EGFR and HER2 receptor tyrosine kinases. It competes with ATP for binding to the kinase domains of these receptors, hindering their downstream signaling pathways that are implicated in cancer cell growth and division. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib targets the epidermal growth factor receptor (EGFR) kinase. It competitively inhibits ATP binding to EGFR, disrupting the downstream signaling pathways responsible for promoting cell proliferation and survival. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Erlotinib is an EGFR tyrosine kinase inhibitor. It binds reversibly to the ATP-binding site of EGFR, suppressing signaling pathways that contribute to cancer cell growth, particularly in lung cancer. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
Afatinib is an irreversible inhibitor of EGFR and HER2 kinases. By forming covalent bonds with the ATP-binding sites of these receptors, it disrupts their signaling cascades, impeding the growth and spread of cancer cells. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Osimertinib targets EGFR with T790M mutation, common in certain lung cancers. It selectively inhibits the mutant EGFR by competing with ATP binding, blocking signaling pathways that drive cancer cell proliferation and survival. | ||||||
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine | 1032900-25-6 | sc-505041 | 1 mg | $230.00 | ||
This targets ALK kinase, particularly in ALK-positive lung cancers. It competes with ATP binding, leading to the inhibition of ALK-driven signaling pathways that contribute to cancer cell proliferation and survival. | ||||||